Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC

Autor:	Jochen K. Lennerz, Jessica J. Lin, Alice T. Shaw, Justin F. Gainor, Lorin A. Ferris, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Alectinib Cancer Research medicine.medical_specialty Crizotinib business.industry 03 medical and health sciences 030104 developmental biology Internal medicine Medicine business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:9093-9093
ISSN:	1527-7755 0732-183X
Popis:	9093Background: Alectinib was recently approved for first-line treatment of advanced ALK+ NSCLC based on the ALEX trial, which demonstrated improved PFS with first-line alectinib compared to crizot...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::983992e776aec2308b46b41bc50865c8 https://doi.org/10.1200/jco.2018.36.15_suppl.9093 Zobrazit plný text záznamu